William J. Gradishar, MD, of Robert H. Lurie Comprehensive Cancer Center of Northwestern University, details the fundamental shift in how clinicians now treat patients with endocrine-sensitive breast cancer, both advanced and early stage, by pairing antihormonal therapy with targeted treatment.
Douglas B. Johnson, MD, MSCI, of Vanderbilt-Ingram Cancer Center, discusses updated guidelines on the use of neoadjuvant therapy, as well as first- and later-line systemic therapies to treat patients with cutaneous melanoma.
Natalie S. Callander, MD, of the University of Wisconsin Carbone Cancer Center, discusses advances in the treatment of patients with multiple myeloma, including her commentary on smoldering disease, the early use of CAR T-cell therapy, quadruplet therapy, and the use of multiple lines of treatment over the disease course.
Wendy Vogel, MSN, FNP, AOCNP, FAPO, of the Advanced Practitioner Society for Hematology and Oncology, summarizes a panel discussion in which she took part, on forming interprofessional oncology care teams that include advanced practitioners. Such collaboration may improve patient outcomes and help practices work more efficiently.
